drug
POMALIDOMIDE
Marketedupdated 5mo agoby Celgene Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(5)
approval · 5
Trials studying POMALIDOMIDE
- phase2Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
- phase3A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
- phase2Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- phase3A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- phase2A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- phase3Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- phase3SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 14, 2027
227 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Dec 21, 2031patentUS 8828427*PED
- Dec 21, 2031patentUS 8828427*PED
- Dec 21, 2031patentUS 8828427*PED
- Dec 21, 2031patentUS 8828427*PED
- Jun 21, 2031compositionUS 88284274.7y
- Jun 21, 2031compositionUS 88284274.7y
- Jun 21, 2031compositionUS 88284274.7y
- Jun 21, 2031compositionUS 88284274.7y
- Nov 19, 2030patentUS 10555939*PED4.1y
- Nov 19, 2030patentUS 10555939*PED4.1y
- Nov 19, 2030patentUS 10555939*PED4.1y
- Nov 19, 2030patentUS 10555939*PED4.1y
- Nov 19, 2030patentUS 9993467*PED4.1y
- Nov 19, 2030patentUS 9993467*PED4.1y
- Nov 19, 2030patentUS 9993467*PED4.1y
- Nov 19, 2030patentUS 9993467*PED4.1y
- May 19, 2030formulationUS 105559393.6y
- May 19, 2030formulationUS 105559393.6y
- May 19, 2030formulationUS 105559393.6y
- May 19, 2030formulationUS 105559393.6y
- May 19, 2030formulationUS 99934673.6y
- May 19, 2030formulationUS 99934673.6y
- May 19, 2030formulationUS 99934673.6y
- May 19, 2030formulationUS 99934673.6y
FDA exclusivities (16)
- Nov 14, 2027PEDPediatric (6mo bonus)1.1y
- Nov 14, 2027PEDPediatric (6mo bonus)1.1y
- Nov 14, 2027PEDPediatric (6mo bonus)1.1y
- Nov 14, 2027PEDPediatric (6mo bonus)1.1y
- May 14, 2027ODE-296Orphan Drug (7y)227d
- May 14, 2027ODE-297Orphan Drug (7y)227d
- May 14, 2027ODE-296Orphan Drug (7y)227d
- May 14, 2027ODE-297Orphan Drug (7y)227d
- May 14, 2027ODE-296Orphan Drug (7y)227d
- May 14, 2027ODE-297Orphan Drug (7y)227d
- May 14, 2027ODE-296Orphan Drug (7y)227d
- May 14, 2027ODE-297Orphan Drug (7y)227d
- Aug 30, 2026PCPC
- Aug 30, 2026PCPC
- Aug 30, 2026PCPC
- Aug 30, 2026PCPC
News(1)
- Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaNovo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.biopharma_dive · 2mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that